NCT03213743

Brief Summary

The purpose of the study is to find out the differential expression profiling of microRNA before and after adiministration of dexmedetomidine in patients undergoing procedures, and then investigators will do some in vitro studies to validate the functions of the microRNA.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 19, 2017

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 21, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 21, 2017

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

July 7, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 11, 2017

Completed
Last Updated

July 11, 2017

Status Verified

July 1, 2017

Enrollment Period

2 days

First QC Date

July 7, 2017

Last Update Submit

July 10, 2017

Conditions

Coronary Disease

Outcome Measures

Primary Outcomes (1)

  • microRNA differential expression

    microRNA differential expression exerts cardioprotection effect on patients undergoing procedures.

    30 minutes

Study Arms (1)

before dexmedetomidine

OTHER

We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.

Drug: Dexmedetomidine Injection

Interventions

Dexmedetomidine InjectionDRUG

Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.

Also known as: Dex group
before dexmedetomidine

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patients without arrithmia will undergo procedure.

You may not qualify if:

  • The patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jinqiao Qian

Kunming, Yunnan, 650032, China

Location

MeSH Terms

Conditions

Coronary Disease

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Jinqiao Qian, Ph.D

    First Affiliated Hospital of Kunming Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 7, 2017

First Posted

July 11, 2017

Study Start

June 19, 2017

Primary Completion

June 21, 2017

Study Completion

June 21, 2017

Last Updated

July 11, 2017

Record last verified: 2017-07

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)